MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-05-2024
Nektar Therapeutics Operating Income 2011-2025 | NKTR
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Nektar Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -264 M | -376 M | -446 M | -425 M | -440 M | 688 M | -59.6 M | -113 M | -29.4 M | -16.5 M | -120 M | -141 M | -124 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 688 M | -446 M | -144 M |
Quarterly Operating Income Nektar Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -54.3 M | - | -117 M | -113 M | -114 M | -110 M | -109 M | -111 M | -103 M | -77.7 M | -134 M | -110 M | -98.7 M | -111 M | -121 M | -100 M | -98.6 M | 974 M | -86.7 M | -24 M | 69.5 M | -50.7 M | -54.4 M | -32.1 M | -32.9 M | -38.3 M | -9.48 M | -29.4 M | 419 K | -43.5 M | 43 M | -37.5 M | 80.3 M | -22.9 M | -36.4 M | -35.9 M | -6.52 M | -32.6 M | -45.1 M | -43.4 M | -32.9 M | -27 M | -37.9 M | -34.5 M | -21.3 M | -34.3 M | -33.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 974 M | -134 M | -30.4 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.92 | 14.97 % | $ 490 M |  Britain |
 |
Aclaris Therapeutics
ACRS
|
-142 M | $ 3.02 | -0.5 % | $ 233 M |  USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 211.4 | 1.16 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
BioVie
BIVI
|
-18.1 M | $ 1.18 | -2.89 % | $ 1.74 M | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |
 |
Catalyst Biosciences
CBIO
|
-67.2 M | $ 12.42 | 0.57 % | $ 818 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 0.17 | -20.57 % | $ 370 M |  Israel |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 95.2 | 0.72 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 26.96 | -0.59 % | $ 1.31 B | USA |
 |
Certara
CERT
|
-1.73 M | $ 8.85 | -0.51 % | $ 1.42 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 9.53 | -0.21 % | $ 140 M | USA |
 |
bluebird bio
BLUE
|
-244 M | - | - | $ 546 M | USA |
 |
Cellectis S.A.
CLLS
|
-131 M | $ 4.93 | 3.79 % | $ 116 M | France |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
58.5 M | $ 581.87 | -0.34 % | $ 44.1 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.55 | 4.08 % | $ 16 M | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | $ 92.76 | -0.15 % | $ 96.9 B | Britain |
 |
ChromaDex Corporation
CDXC
|
7.73 M | - | -0.88 % | $ 598 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 9.25 | 1.82 % | $ 1.49 B | Britain |
 |
CorMedix
CRMD
|
-49 M | $ 12.74 | 1.66 % | $ 649 M | USA |
 |
Celldex Therapeutics
CLDX
|
-195 M | $ 25.91 | -1.87 % | $ 1.67 M | USA |